These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22064394)

  • 1. MS pipeline flowing, but niche remains for neuroprotection.
    Waters H
    Nat Med; 2011 Nov; 17(11):1327. PubMed ID: 22064394
    [No Abstract]   [Full Text] [Related]  

  • 2. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Treatment of Multiple Sclerosis.
    Goldschmidt C; McGinley MP
    Neurol Clin; 2021 Feb; 39(1):21-33. PubMed ID: 33223085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design.
    Kapoor R
    Curr Opin Neurol; 2006 Jun; 19(3):255-9. PubMed ID: 16702831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to neuroprotective strategies in multiple sclerosis.
    Tselis A; Khan OA; Lisak RP
    Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

  • 8. [Multiple sclerosis at the time of world-wide use of disease modifying treatment].
    Gusev EI; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):4-9. PubMed ID: 19894306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linkage between immunomodulation, neuroprotection and neurogenesis.
    Aharoni R; Arnon R
    Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Success of immunomodulators in MS shifts discovery focus to neuroprotection.
    Mullard A
    Nat Rev Drug Discov; 2011 Dec; 10(12):885-7. PubMed ID: 22129976
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapeutic options for multiple sclerosis.
    Curtin F; Hartung HP
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: new insights in pathogenesis and novel therapeutics.
    Ontaneda D; Hyland M; Cohen JA
    Annu Rev Med; 2012; 63():389-404. PubMed ID: 21888515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hindsight is 20/20.
    Moffett AT; Hollander H; Berkenblit G; McArthur JC; Manesh R
    J Hosp Med; 2020 Apr; 15(4):245-249. PubMed ID: 32118562
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O; Kieseier B; Hartung HP
    Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for multiple sclerosis: translational achievements and outstanding needs.
    Haghikia A; Hohlfeld R; Gold R; Fugger L
    Trends Mol Med; 2013 May; 19(5):309-19. PubMed ID: 23582699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis
    Chin P; Chan AC
    Biochemistry; 2018 Feb; 57(5):474-476. PubMed ID: 29172456
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurodegeneration and neuroprotection in multiple sclerosis.
    Stangel M
    Curr Pharm Des; 2012; 18(29):4471-4. PubMed ID: 22612743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying treatments for progressive multiple sclerosis.
    Comi G
    Mult Scler; 2013 Oct; 19(11):1428-36. PubMed ID: 24062415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unified understanding of MS course is required for drug development.
    Coetzee T; Thompson AJ
    Nat Rev Neurol; 2018 Apr; 14(4):191-192. PubMed ID: 29326425
    [No Abstract]   [Full Text] [Related]  

  • 20. New therapeutic approaches for multiple sclerosis.
    De Jager PL; Hafler DA
    Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.